[Retracted] Prognostic Factor Study of Macular Edema Recurrence in Retinal Vein Occlusion after Conbercept Treatment: A Post Hoc Analysis of the FALCON Study

Table 1

Baseline characteristics of the study subjects.

Features	CRVO ()	BRVO ()	value
Mean BCVA (ETDRS letters)			0.02
CRT (median, IQR)	695.5 (592–916)	549.5 (467–656)	0.0002
MV (median, IQR)	13.79 (11.81–17.41)	12.35 (11.27–13.85)	0.015
Regular FAZ contours^1, (%)	15 (50.0%)	8 (26.7%)	0.07
Nonperfusion area (NPA)^2			0.0007
No NP, (%)	13 (43.33%)	1 (3.33%)
<5 PD, (%)	5 (16.67%)	8 (26.67%)
>5 PD, (%)	9 (30.00%)	17 (56.67%)
Macular hemorrhage, (%)	20 (66.67%)	29 (96.67%)	0.006
Macular HE, (%)	3 (10.00%)	7 (23.33%)	0.3
EZ			0.76
Intact, (%)	5 (16.67%)	8 (26.67%)
Disruption in the fovea, (%)	13 (43.33%)	15 (50.00%)
Disruption in the parafovea, (%)	2 (6.67%)	4 (13.33%)
Unevaluable, (%)	10 (33.33%)	3 (10.00%)
OLM		(0.00%)	0.86
Intact, (%)	8 (26.67%)	8 (26.67%)
Disruption in the fovea, (%)	10 (33.33%)	14 (46.67%)
Disruption in the parafovea, (%)	3 (10.00%)	5 (16.67%)
Unevaluable, (%)	9 (30.00%)	3 (10.00%)
DRIL^3, (%)	10 (33.33%)	11 (36.67%)	0.99
IRF			0.0004
No IRF, (%)	0 (0.00%)	1 (3.33%)
Macula area, (%)	1 (3.33%)	10 (33.33%)
Paramacular area, (%)	0 (0.00%)	3 (10.00%)
CME, (%)	29 (96.67%)	16 (53.33%)
SRF			0.73
No SRF, (%)	10 (33.33%)	8 (26.67%)
Small amount, (%)	16 (53.33%)	16 (53.33%)
Large amount, (%)	4 (13.33%)	6 (20.00%)

¹Two unevaluable patients were not included in the analysis. ²Six patients with bleeding events were not included. ³Six patients with unevaluable DRIL were not included. SD: standard deviation; IQR: interquartile range; BCVA: best-corrected visual acuity; CRT: central retina thickness; MV: macular volume; FAZ: foveal avascular zone; NPA: nonperfusion area; PD: papilla diameter; HE: hard exudates; EZ: ellipsoid zone; OLM: outer limiting membrane; DRIL: disorganization of retinal inner layers; IRF: intraretinal fluid; CME: cystoid macular edema; SRF: subretinal Fluid.